Where Tech Meets Bio

Where Tech Meets Bio

Home
Weekly Highlights
Deep Dives
Sponsored Features
About
Weekly Tech+Bio Highlights #76: Neurons, Genomes, and Self-Driving Labs
Living neurons play DOOM, Lilly uses digital twins to scale GLP-1 production, generative genomics are now in Nature, and a rice-grain-sized retinal…
 • BiopharmaTrend, Roman Kasianov, and Andrii Buvailo, PhD
The €25B vs €219B Problem: Europe's Plan to Fix Biotech
Brussels is counting on new laws, sovereign AI, and billions in fresh capital to close the gap. The clock is ticking.
 • BiopharmaTrend
Weekly Tech+Bio Highlights #75: Lilly's Supercomputer, FDA's One-Trial Shift, and China Deals Get Pricey
Generate:Bio's $400M IPO, federated ADMET modeling across five pharma companies, Gilead's $7.8B CAR-T buyout, and an $80M AI-enabled brain health clinic…
 • BiopharmaTrend and Roman Kasianov
Cancer as a Data Problem: What AI Is Doing in Oncology
We track what has moved from promise to proximate execution, from AI-assisted candidate design with 2026 trial targets to agentic workflows that aim to…
 • BiopharmaTrend
Weekly Tech+Bio Highlights #74: Big Pharma AI Tie-Ups Lean Toward Real-World Data
Quick run of pharma-AI collaborations, a new startup based on Google's cell sentence tech, and $100 genome sequencing from San Diego
 • BiopharmaTrend and Roman Kasianov
Join 11k+ biotech industry professionals tracking strategy signals in the 'techbio' space
© 2026 BiopharmaTrend (BPT Analytics Ltd) · Privacy ∙ Terms ∙ Collection notice
Start your SubstackGet the app
Substack is the home for great culture